Analyst Price Target is $42.33
▲ +29.90% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Edgewise Therapeutics in the last 3 months. The average price target is $42.33, with a high forecast of $51.00 and a low forecast of $31.00. The average price target represents a 29.90% upside from the last price of $32.59.
Current Consensus is
Buy
The current consensus among 6 polled investment analysts is to buy stock in Edgewise Therapeutics. This rating has held steady since August 2023, when it changed from a Moderate Buy consensus rating.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Read More